HEИндивидуална стипендия2023–2025

SIREN · Surface-enhanced Raman spectroscopy in liquid biopsy for breast cancer

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период: 2023-10-01 → 2025-09-30
Финансиране от ЕС: 173 847 €
Участници: 3
Схема: HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Наноструктурирани повърхности и оптичен метод за разпознаване на молекулярни следи от рак на гърдата се тестват върху клетъчни модели. Това помага за разработването на по-малко инвазивни методи за ранна диагностика чрез анализ на кръвни проби.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Surface-enhanced Raman spectroscopy in liquid biopsy for breast cancer

Breast cancer is one of the most common cancers worldwide, and early detection is crucial for improving patient outcomes. However, current diagnostic approaches often rely on invasive procedures or lack sufficient sensitivity at early stages. The SIREN project aimed to address this challenge by developing advanced, label-free sensing technologies capable of detecting cancer-related molecular signatures in a minimally invasive way. The project focused on surface-enhanced Raman scattering (SERS), an optical technique that enables highly sensitive molecular fingerprinting. SIREN developed and optimised nanostructured plasmonic substrates designed to improve the robustness and reproducibility of SERS measurements in biologically relevant environments. These platforms were evaluated using purified biomolecules and breast cancer cell models, enabling detailed molecular analysis and high-resolution mapping at the single-cell level. To support the interpretation of complex spectral data, the project also explored data analysis approaches, including machine learning methods. Together, these activities established a technological and methodological foundation for advanced molecular sensing, with the long-term goal of application to serum-based liquid biopsy approaches for cancer research and diagnostics. Beyond its scientific objectives, SIREN contributed to strengthening links between academic research and innovation. By exploring pathways toward scalable sensing technologies and future diagnostic applications, the project supports long-term European efforts in early disease detection, biosensing innovation, and the translation of advanced materials into practical healthcare tools.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Despite current large-scale mammography screening programmes, breast cancer is still the leading cause of cancer death in women in the vast majority of countries. It is recognizable that cancer deaths could be prevented through earlier diagnosis and adequate treatment. Therefore, new vigilant diagnostic tools that could provide an earlier diagnostic should be developed. The progress regarding sensitive, robust, fast, and cost-effective biosensors is a very active research field. Surface-enhanced Raman scattering (SERS) spectroscopy is a powerful technique for ultrasensitive label-free analysis of chemical and biological samples with wide applicability, vastly demonstrated for cancer. Nevertheless, translation of SERS to the clinics and industry is limited due to the lack of reproducible substrates and automation routines to analyze complex spectra. Liquid biopsy is the most commonly used practice for clinical preliminary disease screening. Some groups have already shown noteworthy work addressing the potential of SERS in blood plasma and urine, making it suitable for rapid and minimally invasive cancer diagnosis. SERS can be applied to sense subtle changes in composition and structure of biomolecules in plasma/urine from cancer subjects. Allied to this, discriminant analysis models (DAM) have been applied to SERS. These studies demonstrate that a powerful diagnostic system can be built for cancer screening with very high specificity and sensitivity.The main objective of SIREN is the development of a liquid biopsy test on which highly sensitive solid SERS substrates will detect changes in biomolecular profile between cancer and no cancer samples. Blood plasma and serum, and urine will be used in a label-free detection. Combining with new developed clinical decision-support systems based on SERS spectral analysis the project will provide a classification system for early diagnosis progression and breast cancer in patients.

Оригинален текст от CORDIS (на английски).

Участници

HUMBOLDT-UNIVERSITAET ZU BERLIN · BerlinКоординаторГермания
ISTITUTI CLINICI SCIENTIFICI MAUGERI SOCIETA' PER AZIONI SOCIETA' BENEFIT · PaviaИталия
NANYANG TECHNOLOGICAL UNIVERSITY · SingaporeСингапур